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ABSTRACT
Introduction: Long-term safety data are critical
for evaluating therapies for psoriasis. Ixek-
izumab has demonstrated efficacy and is well
tolerated for the treatment of moderate-to-sev-
ere plaque psoriasis. We examined the safety
and tolerability of up to 5 years of ixekizumab
therapy in patients with psoriasis.
Methods: Integrated safety data were analyzed
from 13 ixekizumab clinical studies. Rates of
treatment-emergent adverse events (TEAEs),
serious AEs (SAEs) and AEs of special interest
were analyzed for the 12-week induction period
in the combined pivotal studies, and for all
pooled studies by year(s) of therapy and overall,
reported as exposure-adjusted incidence rates
(IRs) per 100 patient-years (p-y) and/or
frequencies.
Results: Total ixekizumab exposure was
17,003.4 p-y (N = 5898); 2749 patients
had C 4 years of exposure. When compared
across years of exposure, rates for AEs remained
largely stable or declined, including TEAEs
leading to discontinuation (3.8/100 p-y in year
1, declining to 2.0/100 p-y in year 5); SAEs
(range 6.2–7.0/100 p-y); serious infections
(range 1.3–1.7/100 p-y); nonmelanoma skin
cancer (ranging from 0.5/100 p-y in year 1 toEnhanced Digital Features To view enhanced digital
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0.2/100 p-y in years 4–5); other malignancies
(range 0.4–0.6/100 p-y); inflammatory bowel
disease including ulcerative colitis and Crohn’s
disease (IR 0.2/100 p-y); and major adverse car-
diovascular events (MACE) (range 0.3–0.7/100
p-y). Candidiasis was reported in 327 patients
(IR 1.9/100 p-y), with the majority identified as
mucocutaneous. The rate of injection site reac-
tions was 15.5/100 p-y during year 1 and
2.0–2.3/100 p-y by years 3–5.
Conclusions: The decrease in rates of TEAEs
and the stable rates of SAEs, other malignancies
and MACE during up to 5 years of ixekizumab
dosing are consistent with previous reports
describing a favorable safety profile of ixek-
izumab following shorter durations of exposure.
Funding: Eli Lilly and Company.
Keywords: Adverse events; Etanercept; IL-17;
Integrated analysis; Ixekizumab; Safety;
Psoriasis
Key Summary Points
Psoriasis is a chronic disease that requires
long-term management; thus, long-term
data on the safety and tolerability of
psoriasis treatments are essential to
inform patient management decisions.
We examined the long-term safety and
tolerability of ixekizumab based on dosing
of up to 5 years in 13 clinical trials in
patients with moderate-to-severe
psoriasis.
The incidence rates of treatment-emergent
adverse events, serious adverse events and
adverse events of special interest were
either stable or decreased with increasing
duration of ixekizumab therapy.
These findings are consistent with
previous reports on ixekizumab and
indicate that no new safety findings have
emerged following longer durations of
dosing.
INTRODUCTION
Moderate-to-severe psoriasis is a chronic
immune-mediated inflammatory disease asso-
ciated with substantial comorbidities [1, 2]. At
present, psoriasis requires long-term manage-
ment; thus, long-term data on the safety and
tolerability of treatments are essential to inform
patient management decisions. Ixekizumab is a
high-affinity monoclonal antibody that selec-
tively targets interleukin (IL)-17A [3] and is
approved for the treatment of moderate-to-sev-
ere plaque psoriasis based on the efficacy and
consistent safety profile shown in the
UNCOVER program. IL-17 plays a role in host
mucocutaneous defense, and therefore IL-17
inhibition is linked to adverse events (AEs) in
patients with candidiasis [4–7]. Furthermore,
while the role of IL-17 in inflammatory bowel
disease (IBD) and cardiovascular disease is
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unclear, IL-17 inhibitors are of special interest
in treating these events [8–14]. Overall, the
safety profile of ixekizumab has demonstrated
comparability to biologic therapies with differ-
ent mechanisms of action that are approved
for plaque psoriasis, namely etanercept
(UNCOVER-2 and -3 studies) [15] and ustek-
inumab (IXORA-S study) [16].
Two previous safety updates have addressed
cumulative data from the ixekizumab develop-
ment program. Strober et al. reported safety
data from seven clinical trials (9 April 2015 data
lock) [17]. Langley et al. provided an update of
safety data from 11 clinical trials (15 September
2016 data lock) [18]. Here we report our results
from an examination of the long-term safety
and tolerability of ixekizumab based on
17,003.4 patient-years (p-y) of ixekizumab
exposure from 13 clinical trials (20 September
2018 data lock) in patients with psoriasis.
METHODS
The present analysis included the cumulative
safety data covering up to 319 weeks of ixek-
izumab exposure integrated from 13 controlled
and uncontrolled ixekizumab clinical studies on
psoriasis, including three phase 3, randomized,
double-blind, controlled pivotal clinical studies
(UNCOVER-1, -2 and -3; Fig. 1) [15, 19]. All
patients were C 18 years of age with moderate-
to-severe plaque psoriasis (C 10% body surface
area [BSA] involvement, with the exception of
the IXORA-Q study, in which the cutoff was
C 1% BSA involvement, as the study assessed
genital psoriasis for which a lower threshold is
considered) and had a Static Physician’s Global
Assessment of C 3 and a Psoriasis Area and
Severity Index C 12 at baseline (excepting those
in IXORA-Q). The UNCOVER-1, -2 and -3 and
IXORA-Q [15, 19, 20] studies had 12-week,
randomized, placebo-controlled periods, with
the UNCOVER-2 and -3 studies having an
additional etanercept arm up to week 12. The
IXORA-S study also had an ustekinumab treat-
ment arm; however, the ustekinumab data are
not analyzed herein due to limited patient
numbers (N = 166) and duration of therapy
(52 weeks) [16].
The protocols for all studies included in this
analysis were approved by the Institutional
Review Board or Ethics Committee at each par-
ticipating site. All studies included in this
analysis were conducted in accordance with the
ethical principles of the Declaration of Helsinki.
All eligible patients provided written informed
consent before undergoing study-related
procedures.
Safety Assessments
The AEs for the September 2018 update were
classified based on the Medical Dictionary for
Regulatory Activities version 21.0 (https://www.
meddra.org/sites/default/files/guidance/file/
whatsnew_21_0_english.pdf); data for the pla-
cebo-controlled period of UNCOVER-1, -2 and
-3 were based on version 17.0 (https://www.
meddra.org/sites/default/files/guidance/file/
whatsnew_17_0_english.pdf). A treatment-
emergent AE (TEAE) was an AE that first occur-
red or worsened in severity after baseline and
within the treatment period. The lowest level
terms have been used for the TEAE computa-
tion, and preferred terms are presented. Infec-
tions with an onset date B 14 days before or
after neutrophil count collection were consid-
ered temporally associated with the corre-
sponding neutropenia count. Safety topics of
special interest included injection site reactions
(ISRs), serious infections, candidiasis, major
adverse cardiovascular events (MACE), non-
melanoma skin cancer (NMSC), malignancies
(excluding NMSC) and IBD (including Crohn’s
disease and ulcerative colitis). The IBD events
were adjudicated using the Registre Epidemi-
ologique des Maladies de l’Appareil Digestif
(EPIMAD) criteria [21, 22]. MACE were adjudi-
cated by an external adjudication committee for
ten of the 13 studies (n = 5697).
Statistical Analyses
Data are summarized overall from 13 clinical
studies, and for the induction period (12 weeks)
of three psoriasis clinical studies (UNCOVER-1,
-2 and -3). All randomized patients who
received C 1 dose of the study drug were
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Fig. 1 Designs and numbers of patients for all studies
included in the analysis. aPatients receiving IXE received a
160-mg starting dose of IXE at week 0 prior to receiving
80 mg IXE (Q4W or Q2W). bGlobal studies. cPBO
administered to maintain study blind. dStep-up criteria
determined if dosing increased from 80 mg IXE Q4W to
80 mg IXE Q2W based on whether a patient achieved sPGA
C 2 at 2 consecutive visits during Wk 12 through Wk 40.
eDosing increased from IXE Q4W to IXE Q2W based on
investigator opinion from Wk 24 through Wk 40. fWith-
drawal period (Wks 20–32); a patient was eligible for
treatment with 80 mg IXE Q4W when improvement in
PASI score from baselinewas\75% at any visit betweenWks
20 and 32. gProtocol amendment-mandated dose regimen.
Clinicaltrials.gov numbers: UNCOVER-1, -2, -3, -A and -J,
NCT01474512, NCT01597245, NCT01646177,
NCT01777191 and NCT01624233, respectively; IXORA-
P, -S and -Q, NCT02513550, NCT02561806 and
NCT02718898, respectively; RHBO, NCT02387801;
RHBZ, NCT02634801; RHAJ, NCT01107457; RHBU,
NCT02993471.AC active comparator,DB double-blind,EP
optional extension period after Wk 24 during which patients
received 80 mg IXE Q4W up to Wk 60, ETN 50 mg
etanercept twice weekly, FAE fumaric acid esters 105-mg
starting dose followed by 215 mg given orally 1–3 times per
day, IXE ixekizumab, IXE Q2W ixekizumab every 2 weeks,
IXE Q4W ixekizumab every 4 weeks, IXE Q12W ixekizumab
every 12 weeks, LTE long-term extension,MTX methotrex-
ate 7.5-mg starting dose up to 30 mg given orally once a week,
N number of patients, OL open-label, PAC placebo-
controlled and active comparator, PASI Psoriasis Area
Severity Index, PBO placebo, R randomized, sPGA Static
Physician’s Global Assessment, UST 45 mg ustekinumab
given as subcutaneous injection for participants B 100 kg
and 90 mg subcutaneous injection for participants[ 100 kg
at weeks 0, 4, 16, 28 and 40,Wk week
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included in the safety analysis population. Fre-
quencies or exposure-adjusted incidence rates
(IRs) of AEs are summarized overall and for
some events of interest by 1-year (365-day)
intervals. The IRs are expressed as number of
unique patients with a particular category of
event per 100 p-y, using the entire duration of
exposure during each interval. Multiple AEs
that occurred in different intervals were coun-
ted multiple times.
As long-term control data were not available,
previously published data for the placebo and
ixekizumab groups from the large phase 3
UNCOVER studies are reported as time-adjusted
IRs; baseline characteristics for the same patient
groups are also presented.
RESULTS
A total of 5898 patients received at least one
dose of ixekizumab across the 13 studies (Fig. 1).
Approximately two-thirds of patients were in
the large UNCOVER -1, -2 and -3 studies, which
were ongoing as of the data cutoff for these
analyses. Total patient exposure in the pooled
analysis population was 17,003.4 p-y; 3009
patients had at least 3 years exposure and 2749
had at least 4 years of exposure (Fig. 2). Median
duration of exposure was 1176 days, and maxi-
mum duration of exposure was 2236 days. For
the overall ixekizumab population at baseline,
mean age was 45.8 years, and 67.8% of patients
were male (Table 1). Median duration of psori-
asis symptoms at baseline was 16.7 years.
Placebo-Controlled Period
Results for the combined placebo-controlled
periods of the UNCOVER-1, -2 and -3 studies
have been presented previously [19]. When
adjusted for patient exposure (N = 3119), the IR
of any TEAE was higher with ixekizumab
(255.2/100 p-y) than with placebo (205.5/100
p-y) (Table 2). The most common TEAE repor-
ted was nasopharyngitis for both placebo-
(IR 38.3/100 p-y) and ixekizumab- (IR 40.2/100
p-y) treated patients; the next most common
TEAE was ISR (38.5/100 p-y) among ixek-
izumab-treated patients and upper respiratory
tract infection (15.6/100 p-y) for the placebo
group. For the induction period of the com-
bined UNCOVER-2 and -3 studies (N = 2562),
which included etanercept as an active control,
the rate of any TEAE for ixekizumab (250.5/100
p-y) was similar to that for etanercept (235.8/
100 p-y), and the rates of nasopharyngitis and
ISRs for etanercept were 32.5 and 47.3 per 100
p-y, respectively, versus 35.4 and 41.0 per 100
p-y, respectively, for the combined ixekizumab
arms. Across the UNCOVER studies, for com-
mon TEAEs, IRs through 12 weeks were signifi-
cantly higher among patients receiving
ixekizumab than among those receiving pla-
cebo for ISR and injection site erythema. The IR
of AEs leading to study drug discontinuation
was 5.0/100 p-y for placebo and 9.2/100 p-y for
patients receiving ixekizumab; for discontinua-
tions due to ISRs, there were no AEs among
placebo patients and an IR of 1.1 per 100 p-y
(n = 6; 0.3%) for patients receiving ixekizumab.
The IR of serious AEs (SAEs) was 6.7 per 100 p-y
for patients receiving placebo and 8.6 per 100
p-y for patients receiving ixekizumab during the
induction period. During the induction period
of the combined UNCOVER -2 and -3 studies,
ISRs and injection site erythema were both sig-
nificantly higher for etanercept than for pla-
cebo, while the IR of AEs leading to etanercept
discontinuation was 5.3 per 100 p-y, with three
patients discontinuing due to ISRs (IR 1.8/100
p-y; 0.4%). Similarly, the incidence of SAEs for
Fig. 2 Number of patients by treatment duration. N (total
number of patients) = 5898; total exposure = 17,003.4
patient-years
Dermatol Ther (Heidelb) (2020) 10:133–150 137
Table 1 Baseline characteristics for the overall patient population
Characteristics Placebo
(UNCOVER-1, -2
and -3)
Etanercept
(UNCOVER-2
and -3)
Ixekizumab
(UNCOVER-1, -2
and -3)
Ixekizumab
All
Patients, N 791 739 2328 5898
Age, mean (SD) years 46.2 (12.8) 45.5 (13.3) 45.2 (13.0) 45.8 (13.1)
Male, % (n/N) 70.7 (559/791) 68.2 (504/739) 66.7 (1553/2328) 67.8 (4000/
5898)
Race, % (n/N)
Asian 4.3 (34/791) 2.6 (19/735) 3.7 (86/2323) 6.9 (408/
5892)
African American 3.3 (26/791) 3.1 (23/735) 2.1 (48/2323) 2.9 (168/
5892)
White 91.7 (725/791) 92.7 (681/735) 92.9 (2159/2323) 87.8 (5174/
5892)
Others 0.8 (6/791) 1.6 (12/735) 1.3 (30/2323) 2.4 (142/
5892)
Geographic region, % (n/N)
Asia 1.6 (13/791) 0 0.9 (20/2328) 3.9 (232/
5898)
North America 50.9 (403/791) 51.8 (383/739) 51.4 (1197/2328) 52.6 (3100/
5898)
Europe 42.4 (335/791) 42.4 (313/739) 42.9 (999/2328) 37.4 (2205/
5898)
Central/South America 1.8 (14/791) 4.1 (30/739) 2.5 (58/2328) 3.0 (174/
5898)
Australia 3.3 (26/791) 1.8 (13/739) 2.3 (54/2328) 2.8 (165/
5898)
BMI, mean kg/m2 (SD) 30.5 (7.2) 31.0 (7.4) 30.5 (7.1) 30.6 (7.3)
Prior systemic therapy, % (n/N)
Never 35.8 (283/791) 39.6 (293/739) 34.7 (808/2328) 35.7 (2104/
5898)
Nonbiologic only 31.7 (251/791) 42.1 (311/739) 38.4 (894/2328) 33.7 (1986/
5898)
Biologic only 11.6 (92/791) 8.0 (59/739) 9.3 (216/2328) 12.4 (729/
5898)
Biologic and nonbiologic 20.9 (165/791) 10.3 (76/739) 17.6 (410/2328) 18.3 (1079/
5898)
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etanercept was 8.3 per 100 p-y during the
induction period.
Combined Periods of Ixekizumab Therapy
Incidence rates for TEAEs for the combined
ixekizumab treatment period were compared
with either placebo or ixekizumab treatment
during the induction period. Exposure-adjusted
IRs for any TEAE were lower in the combined
ixekizumab treatment period (30.0/100 p-y)
than in placebo-controlled period (placebo
205.5/100 p-y or ixekizumab 255.2/100 p-y;
Table 2). The same was true for the most com-
mon TEAEs of nasopharyngitis/viral upper res-
piratory infection (8.9/100 p-y overall vs. 38.3/
100 p-y for placebo or 40.2/100 p-y for ixek-
izumab through 12 weeks) upper respiratory
tract infection (5.4/100 p-y overall vs. 15.6/100
p-y or 18.0/100 p-y); ISR (3.4/100 p-y vs. 5.0/100
p-y or 38.5/100 p-y) and headache (3.0/100 p-y
vs. 12.8/100 p-y or 18.9/100 p-y), which were
more common among ixekizumab-treated
patients than placebo-treated patients during
the induction phase. The rates of AEs leading to
study discontinuation, any SAEs and SAEs by
body system generally decreased or remained
static when compared between the induction
period and the combined ixekizumab treatment
period (Table 2).
To assess the impact of cumulative exposure
on rates of important AEs, IRs were compared
through 1, 2, 3, 4 and 5 years of treatment
(Fig. 3). The exposure-adjusted IR of ISRs was
15.5 per 100 p-y during the first year of treat-
ment and declined to a range of 2.0–2.3 per 100
p-y by years 3–5 of treatment. Similarly, allergic
reactions or hypersensitivities were reported at
9.9/100 p-y during the first year of treatment
and declined from 5.1 to 3.8 per 100 p-y from
years 2–5. The IR for AEs leading to study dis-
continuation declined from 3.8/100 p-y in the
first year of treatment to 2.0 per 100 p-y in the
fifth year, while the IR for serious infections
remained essentially constant (range 1.3–1.7
per 100 p-y). IRs of overall SAEs were relatively
constant for each of the 1-year periods (range
6.2–7.0 per 100 p-y). The IRs of NMSC were
Table 1 continued
Characteristics Placebo
(UNCOVER-1, -2
and -3)
Etanercept
(UNCOVER-2
and -3)
Ixekizumab
(UNCOVER-1, -2
and -3)
Ixekizumab
All
Prior biologic therapy, % (n/N)
Never 67.5 (534/791) 81.7 (604/739) 73.1 (1702/2328) 69.3 (4090/
5898)
1 19.6 (155/791) 13.7 (101/739) 16.3 (379/2328) 19.4 (1146/
5898)
2 7.1 (56/791) 3.0 (22/739) 6.2 (144/2328) 6.5 (384/
5898)
C 3 5.8 (46/791) 1.6 (12/739) 4.4 (103/2328) 4.7 (278/
5898)
Duration of psoriasis symptoms,
mean years (SD) [median]
19.1 (12.1) [16.7] 18.5 (12.1) [16.4] 18.8 (12.2) [16.9] 18.7 (12.2)
[16.7]
Tobacco use, yes, % (n/N) 39.5 (310/784) 37.1 (274/739) 37.6 (872/2322) 14.8 (874/
5898)
BMI Body mass index, N total patients evaluated, n number of patients in category, SD standard deviation
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highest in the first year (0.5/100 p-y) and
decreased or stayed the same in subsequent
years (range 0.2–0.4 per 100 p-y), while IRs for
other malignancies ranged from 0.4 per 100 p-y
in the first year to 0.6 per 100 p-y in the fourth
year. MACE occurred in 84/5697 patients, with
an overall IR of 0.5 per 100 p-y (Table 3);
although IRs varied across treatment years, no
trend was observed for an increase over time.
IRs (unadjudicated) of IBD ranged from a high
of 0.5 in the first year to a low of 0.1 during the
third and fourth years of treatment. The IRs of
candidiasis were highest in the first year (3.2/
100 p-y) and then ranged from 2.1 to 2.3 per
100 p-y in subsequent years.
Thirty-four deaths were reported, with 32
deaths occurring during ixekizumab treatment
(IR during treatment 0.2/100 p-y; range 0.1–0.3
per 100 p-y by year). For all deaths, causes were
cardiac-related (n = 14), malignancies (n = 4),
unknown (n = 5), respiratory causes (n = 3),
trauma/accident (n = 3), severe hemorrhagic
cerebral infarction (n = 1), death concomitant
with severe senile dementia (n = 1), ulcerative
colitis (n = 1), cholecystolithiasis (n = 1) and
septic shock (n = 1). MACE accounted for most
deaths, and none of the deaths were considered
related to the study drug.
Adverse Events of Special Interest
As assessed based on years of treatment, IRs were
generally constant or decreasing for ISRs, allergic
reactions/hypersensitivity, serious infections,
candidiasis, MACE, NMSC, other malignancies
and IBD across the treatment periods (Fig. 2).
Administration Site or Drug Reactions
As noted above, the IRs for ISRs, as well as for
allergic reactions/hypersensitivity, decreased
over time through the 5 years of the study.
Table 3 Summary of treatment-emergent adverse events
of special interest during combined ixekizumab dosing
Treatment-emergent AEs N (%) IRa
Patients treated 5898
Injection site reactions 892 (15.1) 5.2
Hypersensitivity/allergic reactions 876 (14.9) 5.2
Serious infections and infestations 223 (3.8) 1.3
Oral candidiasis 140 (2.4) 0.8
Malignancies 131 (2.2) 0.8
NMSC 51 (0.9) 0.3
Other malignancies (excluding
NMSC)
86 (1.5) 0.5
Inflammatory bowel disease (narrow
terms)
26 (0.4) 0.2
Inflammatory bowel disease 1 (0.0) \ 0.05
Crohn’s disease 7 (0.1) \ 0.05
Ulcerative colitis 18 (0.3) 0.1
MACE, adjudicated (n = 5697) 84 (1.5) 0.5
Vascular death 20 (0.4) 0.1
Myocardial infarction, nonfatal 45 (0.8) 0.3
Stroke, nonfatal 20 (0.4) 0.1
AE Adverse event; IR incidence rate; MACE major adverse
cardiovascular events, N total number of patients, n num-
ber of patients in category, NMSC non-melanoma skin
cancer
a Incidence rates are per 100 patient-years
Fig. 3 Treatment-emergent adverse events per 100
patient-years by years of treatment. AE Adverse event,
D/C study discontinuation, IBD inflammatory bowel
disease, MACE major adverse cardiovascular events,
NMSC non-melanoma skin cancer, p-y patient-years, Rx
reaction, SAE serious adverse event
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One or more ISRs were reported for 15.1% of
patients (Table 3), with 10.0, 4.5 and 0.6%
experiencing mild, moderate and severe reac-
tions, respectively, at an overall IR of 5.2 per
100 p-y. The most commonly reported specific
terms were ISR (IR 3.4/100 p-y), injection site
erythema (1.1/100 p-y) and injection site pain
(0.6/100 p-y). A total of 13 patients discontin-
ued the study drug due to injection site–related
TEAEs (0.1/100 p-y). The most frequently
reported allergic events (IR C 0.5) were contact
dermatitis (IR 1.1/100 p-y), eczema (1.0/100
p-y), urticaria (0.6/100 p-y), dermatitis (0.5/100
p-y), allergic rhinitis (0.5/100 p-y) and rash
(0.5/100 p-y). There was one case of worsening
eczematous reaction that was considered a
possible paradoxical reaction, but the patient
recovered and continued in the study. Four
SAEs of pustular psoriasis were reported. One
event occurred after an upper respiratory tract
infection; the patient recovered and continued
in the clinical trial. Of three cases of pustular
psoriasis events, two were considered related to
the study drug by the investigator, and the
third case was considered unrelated; all three
patients discontinued the study drug. There
were reports of potential anaphylaxis events;
however, upon review, none occurred in tem-
poral relationship to the administration of
ixekizumab, and no confirmed cases of ixek-
izumab-related anaphylaxis have been identi-
fied in any clinical studies.
Infections
Infections overall were more common during
the first year of treatment (IR 56.6; 95% con-
fidence interval [CI] 54.6, 58.6/100 p-y) versus
later years (IR range 35.8 [95% CI 33.7, 38.0] to
41.2 [95% CI 39.1, 43.4]/100 p-y). In addition
to the upper respiratory tract infections
described above, the most common infections
overall were bronchitis (IR 2.3/100 p-y),
sinusitis (IR 2.2/100 p-y) and urinary tract
infection (IR 2.0/100 p-y; Table 4). Infections
and infestations were largely mild to moderate
in severity and seldom led to discontinuation
of the study drug (IR for discontinuation due
to infection 0.4/100 p-y). The most common
serious infections (IR C 0.1/100 p-y) were cel-
lulitis (n = 40; IR 0.2/100 p-y); pneumonia
(n = 25; IR 0.1/100 p-y); appendicitis (n = 11;
IR 0.1/100 p-y) and erysipelas (n = 9; IR 0.1/
100 p-y).
Latent tuberculosis was reported for 42
patients (IR 0.2/100 p-y), the mycobacterium
complex test was positive for 43 patients (IR
0.2/100 p-y) and the tuberculin test was posi-
tive for 17 patients (IR 0.1/100 p-y); pulmonary
tuberculosis or tuberculosis was determined for
one patient (IR\0.05/100 p-y) each. These
findings were criteria for discontinuation for
some of the studies and led to discontinuation
in 20, 31, 13, 1 and 1 patients, respectively.
There were no confirmed cases of tuberculosis
reactivation; one de novo case of tuberculosis
was reported in a country with a high tuber-
culosis burden.
Table 4 Infections
Category Combined
ixekizumab
(N = 5898)
n (%) IRa
Patients with C 1 infection 3859 (65.4) 22.7
Nasopharyngitis 1515 (25.7) 8.9
Upper respiratory tract infection 921 (15.6) 5.4
Bronchitis 398 (6.7) 2.3
Sinusitis 369 (6.3) 2.2
Urinary tract infection 333 (5.6) 2.0
Influenza 307 (5.2) 1.8
Pharyngitis 278 (4.7) 1.6
Gastroenteritis 237 (4.0) 1.4
Patients with C 1 serious infection/
infestation
223 (3.8) 1.3
Cellulitis 40 (0.7) 0.2
Pneumonia 25 (0.4) 0.1
Appendicitis 11 (0.2) 0.1
Erysipelas 9 (0.2) 0.1
IR incidence rate, N total number of patients, n number of
patients in category
a Incidence rates are per 100 patient-years
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Malignancies
The most common malignancies were NMSCs
(keratinocyte cancers)—specifically basal cell
carcinoma (n = 42; IR 0.2/100 p-y) and squa-
mous cell carcinomas (n = 12; IR 0.1/100 p-y)
(Table 5). The total number of other malignan-
cies was 86 (IR 0.5/100 p-y), with prostate can-
cer being the most common (n = 12, IR in men
only 0.1/100 p-y), followed by squamous cell
carcinoma (n = 6; IR\0.05/100 p-y for all n B
6), invasive ductal breast carcinoma (n = 5),
colon cancer (n = 4) and metastatic lung cancer
(n = 3); no other specific malignancies were
seen in more than two patients.
Candidiasis
Candidiasis overall was reported by 327 patients
(IR 1.9/100 p-y), with oral candidiasis reported
by 140 patients (IR 0.8/100 p-y) (Table 3); one
case of esophageal candidiasis led to study dis-
continuation; there were no reports of deep
organ or bloodstream Candida infection.
Inflammatory Bowel Disease
Overall, TEAEs of IBD (narrow terms) were
reported by a total of 26 patients (IR 0.2/100
p-y), largely as ulcerative colitis (n = 18; IR 0.1/
100 p-y) and Crohn’s disease (n = 7, IR\0.05/
100 p-y; Table 3). Of the eight reports of
Crohn’s disease from seven patients, four events
occurred in the first year and two each were
reported in the second and fifth years of treat-
ment. As awareness of the role of IL-17 inhibi-
tion in IBD evolved after initiation of the
psoriasis clinical trial program, a protocol
amendment was instituted that allowed for post
hoc adjudication of IBD in a retrospective
manner. Per adjudication, prespecified specific
and nonspecific terms for IBD were identified
and evaluated as follows: 24 patients had
reported IBD confirmed as ulcerative colitis
(n = 16; IR 0.1/100 p-y) and Crohn’s disease
(n = 8; IR\ 0.05/100 p-y). As shown for unad-
judicated cases (specific terms) in Fig. 3, the IR
for adjudicated cases remained relatively con-
stant over time (year 1, n = 14, IR 0.3/100 p-y;
year 2, n = 6, IR 0.2/100 p-y; years 3 and 4, n = 1
each [each IR\ 0.05/100 p-y]; year 5, n = 4,
IR 0.2/100 p-y).
Major Adverse Cardiovascular Events
Major adverse cardiovascular events occurred in
84/5697 patients (IR 0.5/100 p-y) in studies
with adjudication (total p-y 16,455.6) (Table 3).
The most common category of events was
nonfatal myocardial infarction (n = 45; IR 0.3/
100 p-y), followed by vascular death (n = 20;
IR 0.1/100 p-y) and nonfatal stroke (n = 20;
IR 0.1/100 p-y).
DISCUSSION
Many factors must be considered when select-
ing the optimal therapy for psoriasis; important
among these are the association of therapies
with AEs, such as infection or malignancy, and
the impact of therapy on comorbidities [23, 24].
Table 5 Malignancies
Category Combined
ixekizumab
(N = 5898)
IRa
Non-melanoma skin
cancer, n (%)
51 (0.9) 0.3
Basal cell carcinoma,
n (%)
42 (0.7) 0.2
Squamous cell
carcinoma, n (%)
12 (0.2) 0.1
Malignancies excluding
NMSC, n (%)
86 (1.5) 0.5
Prostate cancer,b n (%) 12 (0.3) 0.1
Squamous cell
carcinoma, n (%)
6 (0.1) \ 0.05
Invasive ductal breast
carcinoma, n (%)
5 (0.1) \ 0.05
Colon cancer, n (%) 4 (0.1) \ 0.05
Lung cancer metastatic,
n (%)
3 (0.1) \ 0.05
IR incidence rate, N total number of patients, n number of
patients in category, NMSC non-melanoma skin cancer
a Incidence rates are per 100 patient-years
b Calculated in men only; N = 4000 men with 11,714.2
patient-years of exposure
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We assessed safety events up to 5 years of ther-
apy with ixekizumab in 5898 patients, for
[17,000 total p-y of exposure. IRs of TEAEs
generally decreased or remained stable over
time, and the overall rate of TEAEs was lower
with longer duration of therapy compared to
the first 12-week placebo-controlled period.
Most AEs were not serious, and the rate of dis-
continuation due to AEs was low, with a
decreasing trend over time. The overall rate of
SAEs was stable across the study period, with no
trend toward increasing rates of AEs with longer
duration of exposure. This was also true for rates
of malignancies, MACE and serious infections,
which remained comparable to those for pla-
cebo or ixekizumab during the 12-week pla-
cebo-controlled induction period. These results
support and confirm previous reports describing
a favorable safety profile following shorter
durations of ixekizumab exposure, and suggest
that increased duration and total exposure to
ixekizumab were not associated with additional
or unexpected safety concerns [15, 17, 18].
Previous reports have noted infections as the
most frequent AE associated with ixekizumab
therapy. In the present report, infections were
found to be generally mild to moderate in
severity and seldom led to study discontinua-
tion. The IR of severe infections (1.4/100 p-y)
did not increase over time and was comparable
to that reported in pooled safety data for up to
5 years of treatment with the anti-IL-12 and
anti-IL-23 agent ustekinumab (1.1/100 p-y) [25],
in pooled safety data primarily for 3 years for
the tumor necrosis factor (TNF) inhibitor adal-
imumab (1.8/100 p-y) [26] and in data for up to
66 months in a single study of the Janus kinase
inhibitor tofacitinib (1.2/100 p-y) [27]. There
were no reports of Grade 4 (\ 0.5 9 109/L)
neutropenia associated with infections; an
infection temporally associated with Grade 3
(\1.0–0.5 9 109/L) neutropenia was reported
for three patients (0.1%; influenza [n = 1], otitis
externa [n = 1] and nasopharyngitis [n = 1]) and
infections associated with Grade 2 neutropenia
(\1.5–1.0 9 109/L) were reported for 27 (0.5%)
patients. Consistent with the role of IL-17A in
the suppression of mucocutaneous candidiasis,
oral candidiasis was the most frequently repor-
ted opportunistic infection. Positive tuberculin
tests led to discontinuation (which was protocol
specified for a portion of the studies) for 66
patients. However, no cases of tuberculosis
reactivation have been observed in the ixek-
izumab clinical development program, includ-
ing in patients with latent or previously treated
Mycobacterium tuberculosis infection. One case of
de novo tuberculosis was reported in a country
with a high tuberculosis burden. ISRs were also
one of the most commonly reported AEs, and
their IRs declined over time, as noted in a pre-
vious analysis that used most of the current
dataset [28]. Allergic reactions/hypersensitivi-
ties were more frequently reported during the
first year, then stabilized or decreased moder-
ately in subsequent years. The occurrence of
potential paradoxical reactions, such as pustular
psoriasis, were rare. SAEs classified as allergic
reactions/hypersensitivity events and discon-
tinuation of ixekizumab due to allergic reac-
tions/hypersensitivities were uncommon, with
27 (0.5%) and 28 (0.5%) patients reporting such
events, respectively. Overall, there was no
indication of an increased risk for allergic reac-
tions/hypersensitivity events with increasing
durations of exposure to ixekizumab.
Findings regarding IBD in the present anal-
ysis were consistent with those of an earlier
report on combined ixekizumab safety data
collected over 3 years, indicating that Crohn’s
disease and ulcerative colitis were uncommon
[18]. Annual IRs of patients with TEAEs (specific
and broad terms) adjudicated (retrospective and
prospective) per EPIMAD criteria as probable or
definite Crohn’s disease and ulcerative colitis
did not increase and remained stable for up to
5 years of therapy. As noted in a previous report
on IBD in patients receiving ixekizumab, which
assessed approximately two-thirds of the
patients included herein over shorter periods of
exposure, such rates are comparable to those
reported in psoriasis cohort studies, but are
difficult to compare directly to rates reported in
studies of other biologics due to differences in
criteria for reporting events [22].
Patients with psoriasis are at an increased risk
of cardiovascular AEs, including a 10-year risk of
MACE [29–33]. While a reduction in cardiovas-
cular risk has been suggested for methotrexate
or biologics in the treatment of rheumatoid
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arthritis [34–36], reports on cardiovascular risk
reduction with psoriasis treatment have been
contradictory [37, 38]. Low serum levels of IL-17
have been associated with a risk of repeat
myocardial infarction; however, the role of IL-
17 in atherosclerosis is complex, with conflict-
ing results reported [14]. In the present study,
the overall incidence of MACE of 0.5/100 p-y
was comparable to long-term results reported
for patients receiving ustekinumab (0.44/100
p-y) [25] and adalimumab (0.36/100 p-y) [39],
with no apparent increase in incidence with
longer ixekizumab exposure. Determining
whether biologics, including specific
immunomodulators, are associated with
increased, decreased or comparable rates of
cardiovascular disease relative to rates in
untreated patients with psoriasis or in patients
receiving other psoriasis treatments will require
further studies, such as observational studies or
studies using claims database cohorts, and
meta-analyses with large numbers of patients
receiving various comparator treatments.
Patients with psoriasis may be at increased
risk for some lymphoproliferative [40] and
NMSC malignancies [41, 42], and there are
concerns about the impact of long-term sys-
temic treatment with anti-TNF therapies [43].
The IR of malignancies other than NMSC (0.5/
100 p-y) for up to 5 years of therapy with ixek-
izumab in this study was comparable to that for
long-term ustekinumab (0.6/100 p-y) [25] and
the anti-TNF therapies adalimumab (0.8/100
p-y) [26] and etanercept (estimated 0.55/100
p-y) [44]. The IR of NMSC seen with ixekizumab
of 0.3/100 p-y in this study was somewhat lower
than that reported based on long-term safety
data for ustekinumab (0.52/100 p-y) [25] or with
adalimumab (0.6/100 p-y) [26] or etanercept
(0.9 per 100 p-y) [44] in psoriasis. The ratio of
basal cell carcinoma to squamous cell carci-
noma expected in immunocompetent patients
in the general population is 4:1, and is reversed
in severely immunocompromised patients, such
as transplant recipients [45]; thus, the ratio of
3.5:1 during long-term ixekizumab dosing was
consistent with the expectation for immuno-
competent patients. There were 34 total deaths
reported over the 17,003.4 p-y of exposure to
ixekizumab; the IR of 0.2/100 p-y is consistent
with that reported for ustekinumab up to
5 years (0.22/100 p-y) [25]. Most deaths in this
study were secondary to cardiovascular disor-
ders in patients with background risk factors.
The limitations of the present study include
the following. First, although overall IRs of AEs
decreased after the 12-week induction period,
some of the decreases in AEs may be due to
reporting fatigue and differences in recall due to
increased time between visits at later time
points. Secondly, the lack of a randomized pla-
cebo control group after the induction period
limited our ability to directly compare IRs at
later time points with a control population.
Thirdly, the length of follow-up varied between
studies, and the three largest studies,
UNCOVER-1, -2 and -3, are not all completed;
thus, it will be important to revisit these findings
once all of the UNCOVER studies have been
completed. Fourthly, certain adverse effects,
such as MACE and malignancies, require longer
observation periods and larger patient exposures
to ascertain risk. Long-term safety studies,
including post marketing studies, are ongoing to
continue to evaluate the safety of ixekizumab;
however, preliminary data up to 27 months
from the Corrona observational database are
consistent with the present results [46].
CONCLUSION
In conclusion, no new safety signals were
identified with longer-term follow-up with
ixekizumab, nor was any trend observed for an
increase in IRs for any AE of special interest
based on increased duration of therapy through
1–5 years. Thus, the long-term safety profile
with ixekizumab up to 5 years was consistent
with the favorable safety profile observed pre-
viously following shorter durations of ixek-
izumab exposure.
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